Cost of selective internal radiation therapy versus other modalities

被引：0

作者：

Wasan, Harpreet S. ^{[1
]}

机构：

[1] Univ London Imperial Coll Sci Technol & Med, Hammersmith Hosp, Dept Canc Med, London, England

来源：

FUTURE ONCOLOGY | 2014年 / 10卷 / 15期

关键词：

cost-effectiveness; QALY; radioembolization; selective internal radiation therapy; transarterial chemoembolization; METASTATIC COLORECTAL-CANCER; Y-90; RADIOEMBOLIZATION; CHEMOEMBOLIZATION; MICROSPHERES; CAPECITABINE; BEVACIZUMAB; MITOMYCIN;

D O I：

10.2217/fon.14.235

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：101 / 104

页数：4

共 14 条

[11]

NICE, NICE TECHN ASS TA189

[12]

Seal BS, 2013, J CLIN ONCOL S4, V31

[13] Capecitabine, Bevacizumab, and Mitomycin in First-Line Treatment of Metastatic Colorectal Cancer: Results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study [J].

Tebbutt, Niall C. ;

Wilson, Kate ;

Gebski, Val J. ;

Cummins, Michelle M. ;

Zannino, Diana ;

van Hazel, Guy A. ;

Robinson, Bridget ;

Broad, Adam ;

Ganju, Vinod ;

Ackland, Stephen P. ;

Forgeson, Garry ;

Cunningham, David ;

Saunders, Mark P. ;

Stockler, Martin R. ;

Chua, YuJo ;

Zalcberg, John R. ;

Simes, R. John ;

Price, Timothy J. .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (19) :3191-3198

[14]

Xing MZ, 2013, J COMP EFFECT RES, V2, P435, DOI [10.2217/CER.13.37, 10.2217/cer.13.37]

← 1 2 →